TCG Crossover Management, LLC
- SEC CIK
- 0001839948
- Latest filing
- Aug 14, 2026
Holdings in Q4 2023
Holdings as of Dec 31, 2023, filed Feb 14, 2024. Long positions only; changes compare share counts with Q3 2023.
- Positions
- 29
- +3 vs. Q3 2023
- Portfolio value
- $901.7M
- +$222.6M (+32.8%) vs. Q3 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | 2,109,584 | $86.0M | 9.5% | +606,837+40.4% | Added | History |
| INBXInhibrx Biosciences, Inc. | COM | 1,750,387 | $66.5M | 7.4% | 00.0% | Unchanged | History |
| ICVXIcosavax, Inc. | COM | 3,703,704 | $58.4M | 6.5% | 00.0% | Unchanged | History |
| ANTXAN2 Therapeutics, Inc. | COM | 2,678,209 | $54.9M | 6.1% | 00.0% | Unchanged | History |
| RYZBRayzeBio, Inc. | COM | 869,908 | $54.1M | 6.0% | 00.0% | Unchanged | History |
| JBIOJade Biosciences, Inc. | COM | 2,201,274 | $49.8M | 5.5% | 00.0% | Unchanged | History |
| GERNGeron Corp | COM | 23,375,839 | $49.3M | 5.5% | 00.0% | Unchanged | History |
| SVRASavara Inc | COM | 10,000,000 | $47.0M | 5.2% | 00.0% | Unchanged | History |
| Gracell Biotechnologies Inc38406L103 | SPONSORED ADS | 4,514,786 | $45.3M | 5.0% | +1,475,897+48.6% | Added | – |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 179,917 | $41.6M | 4.6% | 00.0% | Unchanged | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 3,395,495 | $41.6M | 4.6% | 00.0% | Unchanged | History |
| SLNSilence Therapeutics plc | ADS | 2,104,875 | $36.6M | 4.1% | 00.0% | Unchanged | History |
| CMPSCOMPASS Pathways plc | SPONSORED ADS | 3,858,000 | $33.8M | 3.7% | 00.0% | Unchanged | History |
| COGTCogent Biosciences, Inc. | COM | 5,631,042 | $33.1M | 3.7% | 00.0% | Unchanged | History |
| TYRATyra Biosciences, Inc. | COM | 1,989,103 | $27.5M | 3.1% | 00.0% | Unchanged | History |
| TRMLTourmaline Bio, Inc. | COM | 1,007,902 | $26.4M | 2.9% | +1,007,902 | New | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 1,142,857 | $23.1M | 2.6% | 00.0% | Unchanged | History |
| DYNDyne Therapeutics, Inc. | COM | 1,650,150 | $21.9M | 2.4% | 00.0% | Unchanged | History |
| KURAKura Oncology, Inc. | COM | 1,423,642 | $20.5M | 2.3% | 00.0% | Unchanged | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 2,040,816 | $16.2M | 1.8% | 00.0% | Unchanged | History |
| VTGNVistagen Therapeutics, Inc. | COM NEW | 2,676,580 | $13.8M | 1.5% | +2,676,580 | New | History |
| ABVXAbivax S.A. | SPONSORED ADS | 1,100,000 | $11.8M | 1.3% | +1,100,000 | New | History |
| CABACabaletta Bio, Inc. | COM | 486,795 | $11.1M | 1.2% | 00.0% | Unchanged | History |
| TRDAEntrada Therapeutics, Inc. | COM | 584,955 | $8.83M | 1.0% | 00.0% | Unchanged | History |
| NRIXNurix Therapeutics, Inc. | COM | 717,654 | $7.41M | 0.8% | +717,654 | New | History |
| CCCCC4 Therapeutics, Inc. | COM STK | 1,276,574 | $7.21M | 0.8% | 00.0% | Unchanged | History |
| TSHATaysha Gene Therapies, Inc. | COM SHS | 2,912,861 | $5.16M | 0.6% | −8,198,250−73.8% | Reduced | History |
| VTYXVentyx Biosciences, Inc. | COM | 815,724 | $2.01M | 0.2% | 00.0% | Unchanged | History |
| KODKodiak Sciences Inc. | COM | 267,941 | $814.5K | 0.1% | +267,941 | New | History |
Sold out since Q3 2023 (2)
Positions held at the end of Q3 2023 that are gone from this filing.